drugset / Trial / NCT00308308

Efficacy & Safety of Inhaled Insulin in Type 1 Diabetes

NCT00308308

Phase 3 Completed 589 enrolled Mannkind Corporation
RandomizedParallel-groupOpen-labelTreatment

Summary

To determine the safety and efficacy of inhaled insulin in the treatment of type 1 diabetes

Timeline

Start
2006-02
Primary completion
2008-07
Completion
2008-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Insulin Protein / enzyme biologic 15 iu
Subject Insulin Protein / enzyme biologic 30 iu
Comparator insulin glargine Protein / enzyme biologic Subcutaneous